Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 813 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR “I feel extremely proud when I look at what we’ve achieved”: ScottishPower’s Andrew... June 3, 2021 Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... January 23, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab February 26, 2021 Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... February 18, 2021 Load more HOT NEWS Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... “Giving something back”: our supporters are the beating heart of what... K9 Police Officer In Berlin Beats Breast Cancer For Second Time Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK
